Pooled antibiotic susceptibility testing that evaluates how antibiotics perform against the infection as a whole — including in polymicrobial cases. Results in 24–36 hours.
Detects aneuploidy via fluorescence in situ hybridization in patients with hematuria suspected of having bladder cancer.
Designed for use alongside — not instead of — standard urine cytology. Aids initial diagnosis of bladder carcinoma in hematuria patients, and supports subsequent monitoring for tumor recurrence in those previously diagnosed.
Aneuploidy for chromosomes 3, 7, and 17, and loss of the 9p21 locus — via fluorescence in situ hybridization on urine specimens.
Patients with hematuria suspected of having bladder cancer, or those previously diagnosed and being monitored for recurrence.
Urine collected as voided, bladder wash, or catheterized. Alternatively, 30 mL urine mixed with 15 mL PreservCyt at a 2:1 ratio.
Compatible with multiple collection paths so the test fits the visit, not the other way around.
Detects chromosomal abnormalities associated with the development and recurrence of bladder cancer. Delivers positive / negative results in suspicious cystoscopy or atypical cytology cases — without interference from BCG, mitomycin C, or thiotepa in the urine sample.
100% sensitivity among T1 and T2 tumors. Performs without interference from common intravesical agents.
A clear positive / negative result, delivered alongside cytology so the clinician has both lines of evidence in front of them at the moment of decision.
It detects aneuploidy for chromosomes 3, 7, and 17, and loss of the 9p21 locus — chromosomal signals associated with the development and recurrence of bladder cancer.
Patients with hematuria suspected of having bladder cancer, or patients previously diagnosed with bladder cancer who are being monitored for tumor recurrence. Results are intended to be used in conjunction with — not in place of — standard diagnostic procedures such as urine cytology.
Two paths:
No. The test performs without interference in the presence of substances such as BCG, mitomycin C, and thiotepa in the urine sample.
The assay has demonstrated 100% sensitivity among T1 and T2 tumors. As with any FISH-based result, it should be interpreted alongside clinical context and standard cytology.
Connect with a representative to learn how the test fits alongside cytology and cystoscopy in your bladder cancer workflow.